Molecular Analysis and Treatment Options of Thymic Malignancies
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Chemotherapy.
- Who it may be relevant to
- Registry conditions: Thymic Epithelial Tumor, Thymic Carcinoma, Thymic Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Molecular Landscape Analysis and Treatment Options for Thymic Epithelial Tumors
Overview
Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies. In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.
Interventions
- Drug Chemotherapy
different treatments based on the molecular analysis
Primary outcome measures
- Objective response rate (ORR) [Time frame: 20 years]
- Disease control rate (DCR) [Time frame: 20 years]
- Progression-free survival (PFS) [Time frame: 20 years]
Secondary outcome measures (1)
- Overall survival (OS) [Time frame: 20 years]
Eligibility criteria
Inclusion criteria
- Histologically proven diagnosis of thymic malignancies
- 18 years of age or older
- Ability to understand and the willingness to sign a written informed consent document
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
China · 1 center
- Xiaomin Niu — Shanghai
Identifiers
NCT: NCT05667948 · THORACIC002